• The prevalence of germline \textit{BRCA} mutation in ovarian cancer ranges between 6\% and 25\%.

• Only 5 out of 12 guidelines recommend genetic testing for all ovarian cancer patients, regardless of other patient characteristics.

• Testing prerequisites in current guidelines might exclude an estimated 25-30\% of ovarian cancer patients with \textit{BRCA} mutations from germline genetic testing.

• With the availability of \textit{BRCA}-mutation-targeted therapies, identification of ovarian cancer patients with germline \textit{BRCA} mutations has therapeutic consequences.

• Considering the prevalence of germline \textit{BRCA} mutations observed in the different population-based studies of invasive ovarian cancer, and with emerging treatment options for mutation carriers, we recommend testing all patients with non-mucinous, non-borderline epithelial ovarian cancer.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by AstraZeneca. Editorial assistance for this study was provided by Claire Routley of Mudskipper Business Limited. For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).